Literature DB >> 9630091

Outcomes and costs within a disease management program for advanced congestive heart failure.

K A Schulman1, D B Mark, R M Califf.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9630091     DOI： 10.1016/s0002-8703(98)70256-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  4 in total

Review 1.  Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.

Authors:  Emile Levy; Pierre Levy
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.

Authors:  Isao Mitani; Diwakar Jain; Tammy M Joska; Barbara Burtness; Barry L Zaret
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

Review 3.  Economic burden of heart failure in the elderly.

Authors:  Lawrence Liao; Larry A Allen; David J Whellan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Relationship Between Heart Failure Hospitalization Costs and Left Ventricular Ejection Fraction in an Advanced Aging Society.

Authors:  Ryota Kaichi; Kyohei Marume; Michikazu Nakai; Masanobu Ishii; Soshiro Ogata; Yoshitaka Iwanaga; Sou Ikebe; Takayuki Mori; Soichi Komaki; Hiroaki Kusaka; Reiko Toida; Kazumasa Kurogi; Yoshihiro Miyamoto; Nobuyasu Yamamoto
Journal:  Circ Rep       Date:  2021-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.